Carbamazepine
1
Reactions 1404 - 2 Jun 2012 S Carbamazepine Stevens-Johnson syndrome and toxic epidermal necrolysis: 34 case reports A retrospective medical record review identified 10 men and 24 women aged 20–78 years who were diagnosed with carbamazepine-induced Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). The patients were receiving carbamazepine for either trigeminal neuralgia or neuropathic pain [dosages and routes not stated]. Overall, 8 patients developed TEN and 26 developed SJS with symptom onset occurring 1–30 days (mean 10.8 days) after initiation of carbamazepine. All 34 patients had mucosal involvement and the vast majority had eye and/or oral lesions; 10 patients had genital lesions. The patients’ symptoms resolved following withdrawal of carbamazepine. HLA-B genotyping detected the HLA- B*1502 allele in 32 of the 34 patients. Author comment: "HLA-B*1502 is a strong genetic marker for [carbamazepine]-induced SJS/TEN in Thai patients with neuropathic pain. The screening for this marker should be performed prior to initiation of [carbamazepine]". Kulkantrakorn K, et al. HLA-B*1502 Strongly Predicts Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients with Neuropathic Pain. Pain Practice 12: 202-208, No. 3, Mar 2012. Available from: URL: http://dx.doi.org/10.1111/j.1533-2500.2011.00479.x - Thailand 803071161 1 Reactions 2 Jun 2012 No. 1404 0114-9954/10/1404-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
-
Upload
vuongquynh -
Category
Documents
-
view
213 -
download
0
Transcript of Carbamazepine
Reactions 1404 - 2 Jun 2012
SCarbamazepine
Stevens-Johnson syndrome and toxic epidermalnecrolysis: 34 case reports
A retrospective medical record review identified 10 menand 24 women aged 20–78 years who were diagnosed withcarbamazepine-induced Stevens-Johnson syndrome (SJS)or toxic epidermal necrolysis (TEN). The patients werereceiving carbamazepine for either trigeminal neuralgia orneuropathic pain [dosages and routes not stated].
Overall, 8 patients developed TEN and 26 developed SJSwith symptom onset occurring 1–30 days (mean 10.8 days)after initiation of carbamazepine. All 34 patients hadmucosal involvement and the vast majority had eye and/ororal lesions; 10 patients had genital lesions. The patients’symptoms resolved following withdrawal ofcarbamazepine. HLA-B genotyping detected the HLA-B*1502 allele in 32 of the 34 patients.
Author comment: "HLA-B*1502 is a strong genetic markerfor [carbamazepine]-induced SJS/TEN in Thai patients withneuropathic pain. The screening for this marker should beperformed prior to initiation of [carbamazepine]".Kulkantrakorn K, et al. HLA-B*1502 Strongly Predicts Carbamazepine-InducedStevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Thai Patients withNeuropathic Pain. Pain Practice 12: 202-208, No. 3, Mar 2012. Available from:URL: http://dx.doi.org/10.1111/j.1533-2500.2011.00479.x - Thailand 803071161
1
Reactions 2 Jun 2012 No. 14040114-9954/10/1404-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
